Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson’s Prospects


Firing Neurons

koto_feja

Intro

Annovis Bio (NYSE:ANVS) is set to report the results of its Phase 3 trial in early-stage Parkinson’s disease (PD) in the coming weeks. The company’s lead asset, buntanetap (formerly known as posiphen), is a translational inhibitor of alpha synucelein (associated with PD), amyloid precursor

Impression

#

%

Definitive Improvement

4

19%

Suspected/Mild Improvement

4

19%

Unclear/No Effect

2

10%

No Effect

11

52%

Total

21





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *